Guardian Pharmacy Services, Inc. (GRDN)vsNovartis AG ADR (NVS)
GRDN
Guardian Pharmacy Services, Inc.
$41.20
+0.51%
HEALTHCARE · Cap: $2.57B
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3794% more annual revenue ($56.69B vs $1.46B). NVS leads profitability with a 22.5% profit margin vs 3.6%. NVS trades at a lower P/E of 22.0x. NVS earns a higher WallStSmart Score of 51/100 (C-).
GRDN
Hold50
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GRDN.
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Conservative balance sheet, low leverage
Earnings expanding 39.0% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 11.8x book value
2.2% revenue growth
3.6% margin — thin
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : GRDN
The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : GRDN
The primary concerns for GRDN are Price/Book, Revenue Growth, Profit Margin. A P/E of 48.2x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
GRDN is growing revenue faster at 2.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 50/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Guardian Pharmacy Services, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, servicing assisted living and skilled nursing facilities. Known for its commitment to personalized medication management and stringent quality standards, the company leverages advanced technology and deep pharmaceutical expertise to enhance patient outcomes. With an extensive operational presence across multiple states, Guardian is well-positioned to address the growing demand for customized pharmacy services, ensuring optimal operational efficiency for its healthcare partners in an evolving market.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?